<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?</h1>
  <ul>
<li>Libtayo’s performance has been good so far, as sales totaled $661.6 million in the first half of 2025, up 18% year over year.</li>
<li>Image Source: Zacks Investment Research The bottom-line estimate for 2025 has moved up $2.22 to $38.71 over the past 60 days and the same for 2026 has increased 63 cents.</li>
<li>Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%.</li>
<li>Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand.</li>
<li>REGN currently carries a Zacks Rank #3 (Hold).</li>
<li>Today, you can download 7 Best Stocks for the Next 30 Days.</li>
<li>Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/regn-loses-21-1-date-135300786.html">Source</a> · 2025-09-15T13:53:00+00:00</p>
</body>
</html>